Core Viewpoint - The company, Xinwei Medical-B (6609.HK), experienced a significant stock price increase of 14.1% to HKD 57.85 following the announcement of its expected revenue growth and product development progress [1] Financial Performance - The company anticipates revenue for the fiscal year ending December 31, 2025, to be between RMB 400 million and RMB 410 million, representing an increase of at least 43.9% compared to the revenue of RMB 278 million for the fiscal year ending December 31, 2024 [1] - The company expects to report a pre-tax profit of approximately RMB 80 million, a substantial improvement from the pre-tax net loss of RMB 12 million for the fiscal year ending December 31, 2024 [1] Product Development - The company announced that its self-expanding intracranial drug-eluting stent's registration application has been accepted by the National Medical Products Administration of the People's Republic of China [1] - This stent is designed for the treatment of intracranial atherosclerotic stenosis, providing support and opening for narrowed and obstructed lumens, while effectively preventing in-stent restenosis [1] - Currently, there are no similar products approved for market globally, indicating that the company's research and development progress is at a leading level within the industry [1]
港股异动｜多重利好加身 心玮医疗-B大涨14%